NEW YORK (Standard&Poor's) April 23, 2014--Standard&Poor's Ratings Services said today that its ratings on Laval, Quebec-based Valeant Pharmaceuticals International Inc., including the 'BB-' corporate credit rating, are not affected by the company's proposal to acquire Allergan Inc. for about $45 billion in an attempted hostile takeover. The outlook remains stable. Given the considerable uncertainty around the likelihood of an agreement between the two parties, the effect of certain divestitures if the bid is successful, and the final mix and terms of financing we are not commenting at this point on any affect this potential transaction could have on Valeant's rating. Our 'BB-' corporate credit rating on Valeant reflects our view that the company's financial risk profile
